MiR-126-3p was also reported to suppress breast cancer cell growth by targeting insulin receptor substrate-1 (IRS-1) [25], and inhibit proliferation of small cell lung cancer cells by targeting SLC7A5 [16]. This evidence concerns the gene IRS1 and small cell lung carcinoma.